HekaBio K.K. announced that it has secured 552 million JPY (4.9 million USD) in private funding. This funding round was led by Japanese corporates joined by private investors who share HekaBio’s passion for contribution to Japanese society through accelerated access to solutions for unmet medical needs.
HekaBio K.K. was established to specialize in the development and commercialization of innovative therapies originating from overseas, with an initial focus on cancer and autoimmune/inflammatory disorders.
HekaBio’s veteran team leverages its experience and global network developed at two earlier ventures—Junicon K.K., a global medical market research-based consultancy established in Tokyo in 1992, and Vorpal Technologies K.K., a pharmaceutical and medical device CRO established in Tokyo in 2013.
Through this issue of new shares, HekaBio K.K. will continue its portfolio expansion and product development based on the company mission to address the unmet needs of patients and medical professionals in Japan. HekaBio continues to raise capital and is open for further investment as Series A Phase 2 from those who share the company’s passion to contribute to Japan’s healthcare market.
About HekaBio K.K.
HekaBio’s mission is to connect world-leading healthcare innovations to unmet medical needs in Japan, with broad category development expertise in pharma, medical device, in-vitro diagnostics, digital health, and cell & gene therapies. HekaBio targets innovations in oncology, autoimmune/inflammation and neurodegenerative disease that have a high potential for significant therapeutic benefit and healthcare cost savings.
Contact: Mari Tanaka